<DOC>
	<DOCNO>NCT02215122</DOCNO>
	<brief_summary>This crossover study assess systemic pharmacokinetics fluticasone propionate ( FP ) salmeterol ( SAL ) . Study medication administer fix dose combination ( 250 µg FP 50 µg SAL ) Advair® Diskus® , Seretide™ Accuhaler™ CRC749 inhaler .</brief_summary>
	<brief_title>Bioequivalence Study Assess Systemic Exposure FP SAL FDC From Different DPIs</brief_title>
	<detailed_description>Study drug administer inhaled route healthy subject single dos ( three inhalation , i.e . total dose 750 µg FP 150 µg SAL ) . Each subject receive follow treatment random order : A. MGR001 B. Seretide™ Accuhaler™ C. Advair® Diskus® There wash 3 7 day treatment period . Pharmacokinetics assess measurement plasma concentration FP SAL 48 hour follow dosing . Adverse Events collect throughout study .</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year . Body Mass Index ( BMI ) 18 30.5 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . An informed consent document sign date subject . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . A positive urine drug screen . History regular alcohol consumption exceed 14 units/week female 21 units/week male ( 1 unit = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Treatment investigational drug within 30 day 5 halflives determine local requirement , whichever longer , precede first dose study medication . 12lead ECG demonstrate QTcF &gt; 450 msec QRS interval &gt; 120 msec screening . If QTcF exceed 450 msec QRS exceed 120 msec , ECG repeat two time average three QTcF QRS value use determine subject 's eligibility . Hemoglobin &lt; 11.5 g/dL female subject &lt; 12.5 g/dL male subject . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method contraception outline protocol . Use prescription nonprescription drug dietary supplement within 7 day 5 half life ( whichever longer ) prior first dose study medication . Herbal supplement must discontinue least 28 day prior first dose study medication . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . Unwilling unable comply lifestyle guideline describe protocol . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result . Evidence significant history childhood adult asthma , significant history wheeze , chronic cough , dyspnea rest acute bronchospasm . Subjects abnormal lung function test screen , define FEV1 and/or FVC &lt; 80 % predict . Subjects current smoker . Exsmokers give smoke &lt; 6 month and/or smoke pack history ≥10 pack year . Subjects low respiratory tract infection 4 week prior dose . History sensitivity lactose sensitivity ingredient Advair®/Seretide™ , include subject severe milk protein allergy Advair® contraindicate . Subject Investigator subInvestigator , research assistant , pharmacist , study coordinator , staff , relative study personnel directly involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Fluticasone Propionate</keyword>
	<keyword>Salmeterol</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Subjects</keyword>
	<keyword>MGR001</keyword>
	<keyword>CRC749</keyword>
	<keyword>Dry Powder Inhaler</keyword>
	<keyword>generic</keyword>
	<keyword>Advair Diskus</keyword>
	<keyword>Seretide Accuhaler</keyword>
</DOC>